{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028054","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.830641+00:00","generated_at":"2026-06-11T12:45:54.061869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Indaptus Q2 2023 cash $19.7M, Phase 1 trial advances; CMO appointed","bullets":["Cash and marketable securities $19.7M as of June 30, 2023; runway into Q2 2024.","Phase 1 trial (Decoy20) completed first cohort, authorized to advance to second; evidence of immune activation.","Appointed Roger Waltzman, M.D. as Chief Medical Officer, effective Aug 7, 2023.","Q2 2023 net loss per share $0.39 vs $0.46 prior year; G&A down to $2.0M.","Patent allowances in Brazil and India expanded IP protection to 32 countries."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028054","json":"https://secwatch.observer/filing/0001493152-23-028054.json","markdown":"https://secwatch.observer/filing/0001493152-23-028054.md","text":"https://secwatch.observer/filing/0001493152-23-028054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223028054/0001493152-23-028054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223028054/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:45:54.061869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60696e9c795fc8ee26aa1d95b810b20d07a9548e","claim":"Indaptus Therapeutics, Inc. reported second quarter ended June 30, 2023 results: EPS Loss per share for the three months ended June 30, 2023 was approximately $0.39.","evidence_excerpt":"Loss per share for the three months ended June 30, 2023 was approximately $0.39","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223028054/0001493152-23-028054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"EPS","value":"Loss per share for the three months ended June 30, 2023 was approximately $0.39"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}